📄 LATIGO BIOTHERAPEUTICS, INC.

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines targeting NaV1.8 ion channels to block pain transmission without addiction risk. Its lead candidate, LTG-001, is in development for acute pain and has shown positive Phase 2 data, while LTG-321 targets chronic musculoskeletal pain like osteoarthritis. The company aims to build a broad pipeline of pain therapeutics to address significant unmet needs and change the current treatment paradigm. Key risk: We are a clinical-stage biotechnology company with a limited operating history and no history of commercializing products, making it difficult to evaluate our prospects. Proceeds: Advance development of LTG-001 through Phase 3 bunionectomy and open-label safety topline results and to NDA submission, as well as commercial readiness, Advance development of LTG-321 through Phase 2 osteoarthritis pain proof of concept topline results and the start of Phase 3 clinical development, Other r

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines targeting NaV1.8 ion channels to block pain transmission without addiction risk. Its lead candidate, LTG-001, is in development for acute pain and has shown positive Phase 2 data, while LTG-321 targets chronic musculoskeletal pain like osteoarthritis. The company aims to build a broad pipeline of pain therapeutics to address significant unmet needs and change the current treatment paradigm.